NfL and EGFL7 as biomarkers for neuroaxoonal damage and BBB-integrity in neuroinflammation: a translational approach

B14

We hypothesize that marker for BBB-integrity (EGFL7) and neuroaxonal damage (NfL) resolve specific pathophysiologic aspects of Multiple Sclerosis (MS) pathology and that their combination helps to improve monitoring of pathological processes within the CNS and prognostic potential in patients with MS. Therefore we first of all plan to experimentally validate EGFL7 and NfL as markers for BBB-integrity and neuroaxonal damage by taking advantage of human and murine in vitro cultures under different conditions and experimental models of acute (focal inflammatory lesion, relapsing-remitting EAE, stroke) and chronic neuronal injury (chronic EAE models). In a second step we plan to unravel the influence of lesion localization within the CNS and their clearance routes from the CNS to the periphery (by modulating meningeal lymphatics, BBB-drainage and myeloid clearance function), on the peripheral marker levels. In a third step we plan to translate our findings to the patient using prospective multicenter cohorts (NationMS, Nalo-MS, Z02).

 

 

 

 

 

 

 

 

 

 

Principal Investigators:

Dr. med. Timo Uphaus
Klinik für Neurologie
Mainz
Timo.Uphaus@unimedizin-mainz.de

Univ.-Prof. Dr. med. Frauke Zipp
Klinik für Neurologie
Mainz
frauke.zipp@unimedizin-mainz.de

News

Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more
Wed, 20/01/2021
A new study on neurological manifestations of severe COVID-19 reveals nervous system immune deficiency
Patients suffering from COVID-19 can develop concomitant and long-term symptoms in their nervous system. The most common symptom in this context is the loss of the sense of smell and taste, while more severe symptoms such as stroke, cerebral seizures, or meningitis are possible. A team of scientists from the medical faculties at the Universities […]...more